Skip to main content
BoF Logo

Agenda-setting intelligence, analysis and advice for the global fashion community.

Novo Nordisk Hikes 2026 Outlook Again

The Ozempic maker raised its full-year outlook for the third time this year on Wednesday as its Wegovy pill beat third-quarter sales forecasts, boosting the Danish firm’s bid to win back ground from US rival Eli Lilly.
Novo Nordisk
Novo is clawing back into the obesity drug race after sliding sales and shares in recent years. (Getty)
PREFER BoF ON GOOGLE
In This Article

© 2026 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

Loading recommended reads…

Latest News & Analysis
Unrivalled, world class journalism across fashion, luxury and beauty industries.
VIEW MORE
Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON
Voices 2026 - Global Livestream, December 1-3